J Korean Neurosurg Soc.  2015 Jun;57(6):415-421. 10.3340/jkns.2015.57.6.415.

Moyamoya Biomarkers

• Smith ER

• KMID: 2191247
• DOI: http://doi.org/10.3340/jkns.2015.57.6.415

Abstract

Moyamoya disease (MMD) is an arteriopathy of the intracranial circulation predominantly affecting the branches of the internal carotid arteries. Heterogeneity in presentation, progression and response to therapy has prompted intense study to improve the diagnosis and prognosis of this disease. Recent progress in the development of moyamoya-related biomarkers has stimulated marked interest in this field. Biomarkers can be defined as biologically derived agents-such as specific molecules or unique patterns on imaging-that can identify the presence of disease or help to predict its course. This article reviews the current categories of biomarkers relevant to MMD-including proteins, cells and genes-along with potential limitations and applications for their use.

Keyword

Moyamoya; Biomarker; Stroke; Genetics; Proteome

MeSH Terms

Biomarkers*
Carotid Artery, Internal
Diagnosis
Genetics
Moyamoya Disease
Population Characteristics
Prognosis
Proteome
Stroke
Proteome

Reference

1. Amano T, Inoha S, Wu CM, Matsushima T, Ikezaki K. Serum alpha1-antitrypsin level and phenotype associated with familial moyamoya disease. Childs Nerv Syst. 2003; 19:655–658. PMID: 12955420.

2. Araki Y, Yoshikawa K, Okamoto S, Sumitomo M, Maruwaka M, Wakabayashi T. Identification of novel biomarker candidates by proteomic analysis of cerebrospinal fluid from patients with moyamoya disease using SELDI-TOF-MS. BMC Neurol. 2010; 10:112. PMID: 21059247.

3. Baird LC, Smith ER, Ichord R, Piccoli DA, Bernard TJ, Spinner NB, et al. Moyamoya syndrome associated with Alagille syndrome : outcome after surgical revascularization. J Pediatr. 2015; 166:470–473. PMID: 25465847.

4. Bernard TJ, Fenton LZ, Apkon SD, Boada R, Wilkening GN, Wilkinson CC, et al. Biomarkers of hypercoagulability and inflammation in childhood-onset arterial ischemic stroke. J Pediatr. 2010; 156:651–656. PMID: 20022340.

5. Choi H, Phi JH, Paeng JC, Kim SK, Lee YS, Jeong JM, et al. Imaging of integrin α(V)β(3) expression using (68)Ga-RGD positron emission tomography in pediatric cerebral infarct. Mol Imaging. 2013; 12:213–217. PMID: 23651498.

6. Codd PJ, Scott RM, Smith ER. Seckel syndrome and moyamoya. J Neurosurg Pediatr. 2009; 3:320–324. PMID: 19338412.

7. Fujimura M, Watanabe M, Narisawa A, Shimizu H, Tominaga T. Increased expression of serum Matrix Metalloproteinase-9 in patients with moyamoya disease. Surg Neurol. 2009; 72:476–480. discussion 480PMID: 19147196.

8. Fujiwara H, Momoshima S, Kuribayashi S. Leptomeningeal high signal intensity (ivy sign) on fluid-attenuated inversion-recovery (FLAIR) MR images in moyamoya disease. Eur J Radiol. 2005; 55:224–230. PMID: 16036151.

9. Fukui M. Guidelines for the diagnosis and treatment of spontaneous occlusion of the circle of Willis ('moyamoya' disease). Research Committee on Spontaneous Occlusion of the Circle of Willis (Moyamoya Disease) of the Ministry of Health and Welfare, Japan. Clin Neurol Neurosurg. 1997; 99(Suppl 2):S238–S240. PMID: 9409446.

10. Goda M, Isono M, Ishii K, Kamida T, Abe T, Kobayashi H. Long-term effects of indirect bypass surgery on collateral vessel formation in pediatric moyamoya disease. J Neurosurg. 2004; 100(2 Suppl Pediatrics):156–162. PMID: 14758943.

11. Guo DC, Papke CL, Tran-Fadulu V, Regalado ES, Avidan N, Johnson RJ, et al. Mutations in smooth muscle alpha-actin (ACTA2) cause coronary artery disease, stroke, and Moyamoya disease, along with thoracic aortic disease. Am J Hum Genet. 2009; 84:617–627. PMID: 19409525.

12. Han H, Pyo CW, Yoo DS, Huh PW, Cho KS, Kim DS. Associations of Moyamoya patients with HLA class I and class II alleles in the Korean population. J Korean Med Sci. 2003; 18:876–880. PMID: 14676447.

13. Harada M, Miyoshi H, Uno M, Okada T, Hisaoka S, Hori A, et al. Neuronal impairment of adult moyamoya disease detected by quantified proton MRS and comparison with cerebral perfusion by SPECT with tc-99m HM-PAO : a trial of clinical quantification of metabolites. J Magn Reson Imaging. 1999; 10:124–129. PMID: 10441014.

14. Hishikawa T, Tokunaga K, Sugiu K, Date I. Clinical and radiographic features of moyamoya disease in patients with both cerebral ischaemia and haemorrhage. Br J Neurosurg. 2013; 27:198–201. PMID: 22934580.

15. Hojo M, Hoshimaru M, Miyamoto S, Taki W, Nagata I, Asahi M, et al. Role of transforming growth factor-beta1 in the pathogenesis of moyamoya disease. J Neurosurg. 1998; 89:623–629. PMID: 9761057.

16. Hong SH, Wang KC, Kim SK, Cho BK, Park MH. Association of HLA-DR and -DQ genes with familial moyamoya disease in Koreans. J Korean Neurosurg Soc. 2009; 46:558–563. PMID: 20062572.

17. Ikeda H, Sasaki T, Yoshimoto T, Fukui M, Arinami T. Mapping of a familial moyamoya disease gene to chromosome 3p24.2-p26. Am J Hum Genet. 1999; 64:533–537. PMID: 9973290.

18. Inoue TK, Ikezaki K, Sasazuki T, Matsushima T, Fukui M. Linkage analysis of moyamoya disease on chromosome 6. J Child Neurol. 2000; 15:179–182. PMID: 10757474.

19. Jackson EM, Lin N, Manjila S, Scott RM, Smith ER. Pial synangiosis in patients with moyamoya younger than 2 years of age. J Neurosurg Pediatr. 2014; 13:420–425. PMID: 24527861.

20. Jung KH, Chu K, Lee ST, Park HK, Kim DH, Kim JH, et al. Circulating endothelial progenitor cells as a pathogenetic marker of moyamoya disease. J Cereb Blood Flow Metab. 2008; 28:1795–1803. PMID: 18612318.

21. Kainth DS, Chaudhry SA, Kainth HS, Suri FK, Qureshi AI. Prevalence and characteristics of concurrent down syndrome in patients with moyamoya disease. Neurosurgery. 2013; 72:210–215. discussion 215PMID: 23149966.

22. Kamada F, Aoki Y, Narisawa A, Abe Y, Komatsuzaki S, Kikuchi A, et al. A genome-wide association study identifies RNF213 as the first Moyamoya disease gene. J Hum Genet. 2011; 56:34–40. PMID: 21048783.

23. Kang HS, Kim JH, Phi JH, Kim YY, Kim JE, Wang KC, et al. Plasma matrix metalloproteinases, cytokines and angiogenic factors in moyamoya disease. J Neurol Neurosurg Psychiatry. 2010; 81:673–678. PMID: 19965844.

24. Kang HS, Moon YJ, Kim YY, Park WY, Park AK, Wang KC, et al. Smooth-muscle progenitor cells isolated from patients with moyamoya disease : novel experimental cell model. J Neurosurg. 2014; 120:415–425. PMID: 24160477.

25. Kashiwagi S, Yamashita T, Katoh S, Kitahara T, Nakashima K, Yasuhara S, et al. Regression of moyamoya vessels and hemodynamic changes after successful revascularization in childhood moyamoya disease. Acta Neurol Scand Suppl. 1996; 166:85–88. PMID: 8686450.

26. Kawaguchi S, Sakaki T, Morimoto T, Kakizaki T, Kamada K. Characteristics of intracranial aneurysms associated with moyamoya disease. A review of 111 cases. Acta Neurochir (Wien). 1996; 138:1287–1294. PMID: 8980731.

27. Kawashima M, Noguchi T, Takase Y, Nakahara Y, Matsushima T. Decrease in leptomeningeal ivy sign on fluid-attenuated inversion recovery images after cerebral revascularization in patients with Moyamoya disease. AJNR Am J Neuroradiol. 2010; 31:1713–1718. PMID: 20466798.

28. Kelly ME, Bell-Stephens TE, Marks MP, Do HM, Steinberg GK. Progression of unilateral moyamoya disease : a clinical series. Cerebrovasc Dis. 2006; 22:109–115. PMID: 16685122.

29. Kennedy BC, McDowell MM, Yang PH, Wilson CM, Li S, Hankinson TC, et al. Pial synangiosis for moyamoya syndrome in children with sickle cell anemia : a comprehensive review of reported cases. Neurosurg Focus. 2014; 36:E12. PMID: 24380478.

30. Khan N, Yonekawa Y. Moyamoya angiopathy in Europe. Acta Neurochir Suppl. 2005; 94:149–152. PMID: 16060256.

31. Kim JH, Jung JH, Phi JH, Kang HS, Kim JE, Chae JH, et al. Decreased level and defective function of circulating endothelial progenitor cells in children with moyamoya disease. J Neurosci Res. 2010; 88:510–518. PMID: 19774676.

32. Kim SK, Yoo JI, Cho BK, Hong SJ, Kim YK, Moon JA, et al. Elevation of CRABP-I in the cerebrospinal fluid of patients with Moyamoya disease. Stroke. 2003; 34:2835–2841. PMID: 14605320.

33. Kim YI, Phi JH, Paeng JC, Choi H, Kim SK, Lee YS, et al. In vivo evaluation of angiogenic activity and its correlation with efficacy of indirect revascularization surgery in pediatric moyamoya disease. J Nucl Med. 2014; 55:1467–1472. PMID: 25060195.

34. Kirkham FJ, DeBaun MR. Stroke in children with sickle cell disease. Curr Treat Options Neurol. 2004; 6:357. PMID: 15279758.

35. Koss M, Scott RM, Irons MB, Smith ER, Ullrich NJ. Moyamoya syndrome associated with neurofibromatosis Type 1 : perioperative and long-term outcome after surgical revascularization. J Neurosurg Pediatr. 2013; 11:417–425. PMID: 23373626.

36. Kuroda S, Hashimoto N, Yoshimoto T, Iwasaki Y. Research Committee on Moyamoya Disease in Japan. Radiological findings, clinical course, and outcome in asymptomatic moyamoya disease : results of multicenter survey in Japan. Stroke. 2007; 38:1430–1435. PMID: 17395863.

37. Kuroda S, Ishikawa T, Houkin K, Nanba R, Hokari M, Iwasaki Y. Incidence and clinical features of disease progression in adult moyamoya disease. Stroke. 2005; 36:2148–2453. PMID: 16179571.

38. Kusaka N, Sugiu K, Tokunaga K, Katsumata A, Nishida A, Namba K, et al. Enhanced brain angiogenesis in chronic cerebral hypoperfusion after administration of plasmid human vascular endothelial growth factor in combination with indirect vasoreconstructive surgery. J Neurosurg. 2005; 103:882–890. PMID: 16304993.

39. Lee JY, Kim SK, Cheon JE, Choi JW, Phi JH, Kim IO, et al. Posterior cerebral artery involvement in moyamoya disease : initial infarction and angle between PCA and basilar artery. Childs Nerv Syst. 2013; 29:2263–2269. PMID: 23653141.

40. Lin N, Baird L, Koss M, Kopecky KE, Gone E, Ullrich NJ, et al. Discovery of asymptomatic moyamoya arteriopathy in pediatric syndromic populations : radiographic and clinical progression. Neurosurg Focus. 2011; 31:E6.

41. Liu W, Morito D, Takashima S, Mineharu Y, Kobayashi H, Hitomi T, et al. Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development. PLoS One. 2011; 6:e22542. PMID: 21799892.

42. Malek AM, Connors S, Robertson RL, Folkman J, Scott RM. Elevation of cerebrospinal fluid levels of basic fibroblast growth factor in moyamoya and central nervous system disorders. Pediatr Neurosurg. 1997; 27:182–189. PMID: 9577971.

43. Maruwaka M, Yoshikawa K, Okamoto S, Araki Y, Sumitomo M, Kawamura A, et al. Biomarker research for moyamoya disease in cerebrospinal fluid using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. J Stroke Cerebrovasc Dis. 2015; 24:104–111. PMID: 25440344.

44. Masuda J, Ogata J, Yutani C. Smooth muscle cell proliferation and localization of macrophages and T cells in the occlusive intracranial major arteries in moyamoya disease. Stroke. 1993; 24:1960–1967. PMID: 7902623.

45. Mineharu Y, Liu W, Inoue K, Matsuura N, Inoue S, Takenaka K, et al. Autosomal dominant moyamoya disease maps to chromosome 17q25.3. Neurology. 2008; 70(24 Pt 2):2357–2363. PMID: 18463369.

46. Miyatake S, Miyake N, Touho H, Nishimura-Tadaki A, Kondo Y, Okada I, et al. Homozygous c.14576G>A variant of RNF213 predicts early-onset and severe form of moyamoya disease. Neurology. 2012; 78:803–810. PMID: 22377813.

47. Moftakhar P, Smith ER, Choulakian A, Scott RM, Danielpour M. Moyamoya disease in children with congenital dwarfing conditions. Pediatr Neurosurg. 2010; 46:373–380. PMID: 21389750.

48. Munot P, Saunders DE, Milewicz DM, Regalado ES, Ostergaard JR, Braun KP, et al. A novel distinctive cerebrovascular phenotype is associated with heterozygous Arg179 ACTA2 mutations. Brain. 2012; 135(Pt 8):2506–2514. PMID: 22831780.

49. Nanba R, Kuroda S, Ishikawa T, Houkin K, Iwasaki Y. Increased expression of hepatocyte growth factor in cerebrospinal fluid and intracranial artery in moyamoya disease. Stroke. 2004; 35:2837–2842. PMID: 15528455.

50. Ni G, Liu W, Huang X, Zhu S, Yue X, Chen Z, et al. Increased levels of circulating SDF-1α and CD34+ CXCR4+ cells in patients with moyamoya disease. Eur J Neurol. 2011; 18:1304–1309. PMID: 21435112.

51. Qaiser R, Scott RM, Smith ER. Identification of an association between Robinow syndrome and moyamoya. Pediatr Neurosurg. 2009; 45:69–72. PMID: 19258733.

52. Qureshi IA, Mehler MF. Emerging role of epigenetics in stroke : part 1 : DNA methylation and chromatin modifications. Arch Neurol. 2010; 67:1316–1322. PMID: 21060009.

53. Qureshi IA, Mehler MF. The emerging role of epigenetics in stroke : II. RNA regulatory circuitry. Arch Neurol. 2010; 67:1435–1441. PMID: 21149808.

54. Roach ES, Golomb MR, Adams R, Biller J, Daniels S, Deveber G, et al. Management of stroke in infants and children : a scientific statement from a Special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young. Stroke. 2008; 39:2644–2691. PMID: 18635845.

55. Roder C, Peters V, Kasuya H, Nishizawa T, Wakita S, Berg D, et al. Analysis of ACTA2 in European Moyamoya disease patients. Eur J Paediatr Neurol. 2011; 15:117–122. PMID: 20970362.

56. Romeo MJ, Espina V, Lowenthal M, Espina BH, Petricoin EF 3rd, Liotta LA. CSF proteome : a protein repository for potential biomarker identification. Expert Rev Proteomics. 2005; 2:57–70. PMID: 15966853.

57. Sakurai K, Horiuchi Y, Ikeda H, Ikezaki K, Yoshimoto T, Fukui M, et al. A novel susceptibility locus for moyamoya disease on chromosome 8q23. J Hum Genet. 2004; 49:278–281. PMID: 15362573.

58. Scott RM, Smith ER. Moyamoya disease and moyamoya syndrome. N Engl J Med. 2009; 360:1226–1237. PMID: 19297575.

59. Scott RM, Smith JL, Robertson RL, Madsen JR, Soriano SG, Rockoff MA. Long-term outcome in children with moyamoya syndrome after cranial revascularization by pial synangiosis. J Neurosurg. 2004; 100(2 Suppl Pediatrics):142–149. PMID: 14758941.

60. Shimojima K, Yamamoto T. ACTA2 is not a major disease-causing gene for moyamoya disease. J Hum Genet. 2009; 54:687–688. PMID: 19745835.

61. Smith ER, McClain CD, Heeney M, Scott RM. Pial synangiosis in patients with moyamoya syndrome and sickle cell anemia : perioperative management and surgical outcome. Neurosurg Focus. 2009; 26:E10. PMID: 19335126.

62. Smith ER, Scott RM. Progression of disease in unilateral moyamoya syndrome. Neurosurg Focus. 2008; 24:E17. PMID: 18275294.

63. Smith ER, Scott RM. Spontaneous occlusion of the circle of Willis in children : pediatric moyamoya summary with proposed evidence-based practice guidelines. A review. J Neurosurg Pediatr. 2012; 9:353–360. PMID: 22462697.

64. Smith JJ, Sorensen AG, Thrall JH. Biomarkers in imaging : realizing radiology's future. Radiology. 2003; 227:633–638. PMID: 12663828.

65. Soriano SG, Cowan DB, Proctor MR, Scott RM. Levels of soluble adhesion molecules are elevated in the cerebrospinal fluid of children with moyamoya syndrome. Neurosurgery. 2002; 50:544–549. PMID: 11841722.

66. Strimbu K, Tavel JA. What are biomarkers? Curr Opin HIV AIDS. 2010; 5:463–466. PMID: 20978388.

67. Sugiyama T, Kuroda S, Nakayama N, Tanaka S, Houkin K. Bone marrow-derived endothelial progenitor cells participate in the initiation of moyamoya disease. Neurol Med Chir (Tokyo). 2011; 51:767–773. PMID: 22123479.

68. Suzuki J, Takaku A. Cerebrovascular "moyamoya" disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol. 1969; 20:288–299. PMID: 5775283.

69. Takahashi A, Sawamura Y, Houkin K, Kamiyama H, Abe H. The cerebrospinal fluid in patients with moyamoya disease (spontaneous occlusion of the circle of Willis) contains high level of basic fibroblast growth factor. Neurosci Lett. 1993; 160:214–216. PMID: 8247356.

70. Takeuchi K, Shimizu K. Hypoplasia of the bilateral internal carotid arteries. No To Shinkei. 1957; 9:37–43.

71. Ullrich NJ, Robertson R, Kinnamon DD, Scott RM, Kieran MW, Turner CD, et al. Moyamoya following cranial irradiation for primary brain tumors in children. Neurology. 2007; 68:932–938. PMID: 17372129.

72. Yamada M, Fujii K, Fukui M. [Clinical features and outcomes in patients with asymptomatic moyamoya disease--from the results of nation-wide questionnaire survey]. No Shinkei Geka. 2005; 33:337–342. PMID: 15830539.

73. Yanagawa Y, Sugiura T, Suzuki K, Okada Y. Moyamoya disease associated with positive findings for rheumatoid factor and myeloperoxidase-anti-neutrophil cytoplasmic antibody. West Indian Med J. 2007; 56:282–284. PMID: 18072414.

74. Yoshihara T, Taguchi A, Matsuyama T, Shimizu Y, Kikuchi-Taura A, Soma T, et al. Increase in circulating CD34-positive cells in patients with angiographic evidence of moyamoya-like vessels. J Cereb Blood Flow Metab. 2008; 28:1086–1089. PMID: 18231114.

75. Yoshimoto T, Houkin K, Takahashi A, Abe H. Angiogenic factors in moyamoya disease. Stroke. 1996; 27:2160–2165. PMID: 8969773.